Organisation paid for research Program year 2025 Source: CMS Open Payments

Vaught Neurological Services PLLC

Neither a doctor nor a teaching hospital

Research payments

$507,685

23 payments

Through program year 2025, Vaught Neurological Services PLLC is reported as receiving $507,685 in research payments, across 23 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $124,418 11
2024 Research $204,586 2
2023 Research $153,751 2
2022 Research $10,640 3
2021 Research $7,000 2
2020 Research $6,069 2
2019 Research $1,222 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $452,590 8 payments
  2. AbbVie, Inc. $43,095 12 payments
  3. ACADIA Pharmaceuticals Inc $7,000 2 payments
  4. Teva Pharmaceuticals USA, Inc. $5,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib $450,299 6 payments
  2. Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine $30,450 7 payments
  3. Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor $10,640 3 payments
  4. ACA 16-cAC-0001 $7,000 2 payments
  5. A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice $5,000 1 payment
  6. Long Term Prospective Multinational Parallel Cohort Study Monitoring Safety in Patients With Multiple Sclerosis Newly Started With Fingolimod Once Daily Or Treated With Another Approved Disease Modifying Therapy $2,291 2 payments
  7. Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine $1,805 1 payment
  8. M23-714 Ubrelvy Menstrual Migraine $200 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record